Clinical Trial Update: Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the feasibility and safety of donor-derived natural killer cell infusions to prevent leukemia relapse after hematopoietic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Mixed Phenotype Acute Leukemia
• T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Donor-derived natural killer cell infusion (donor-derived natural killer cells)

Snippet

Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic T-cell Leukemia | Phase 2 | Status: RECRUITING